Fresenius Kabi to buy Akorn for $4.3 billion
LAKE ZURICH, Ill., and LAKE FOREST, Ill. — Global health care company Fresenius Kabi plans to acquire U.S. prescription and over-the-counter drug maker Akorn for $4.3 billion. Under the deal, announced late Monday, Fresenius Kabi agreed to buy Akorn $34 per share, plus the assume about $450 million of debt. The U.S. headquarters for Akorn
